SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-19-006304
Filing Date
2019-03-05
Accepted
2019-03-05 20:43:31
Documents
2
Period of Report
2019-02-25

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1631
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4508
  Complete submission text file 0000899243-19-006304.txt   7572
Mailing Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Issuer) CIK: 0001629137 (see all company filings)

IRS No.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address
CATHERS BRIAN EDWIN (Reporting) CIK: 0001769127 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37539 | Film No.: 19660963